Table 3.

Association between exposure to aspirin and COVID-19 related complications (groups 1 and 2).

	Case patients (%)	Control patients (%)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Adjusted OR (95% CI)
Group 1
Complication	339 (100)	339 (100)		Model 1∗	Model 2†
Non-exposure to aspirin	262 (77.3)	281 (82.9)	1.00	1.00	1.00
Exposure to aspirin	77 (22.7)	58 (17.1)	1.48 (0.99–2.20)	1.06 (0.66–1.69)	1.07 (0.65–1.75)
Death	128 (100)	128 (100)
Non-exposure to aspirin	91 (71.1)	97 (75.8)	1.00	1.00	1.00
Exposure to aspirin	37 (28.9)	31 (24.2)	1.26 (0.73–2.18)	0.92 (0.46–1.84)	0.76 (0.34–1.71)

Group 2
Complication	530 (100)	530 (100)		Model 1∗
Nonexposure to aspirin	418 (78.9)	433 (81.7)	1.00	1.00	–
Exposure to aspirin	112 (21.1)	97 (18.3)	1.21 (0.88–1.64)	0.91 (0.64–1.29)	–
Death	210 (100)	210 (100)
Non-exposure to aspirin	152 (72.4)	156 (74.3)	1.00	1.00	–
Exposure to aspirin	58 (27.6)	54 (25.7)	1.10 (0.72–1.66)	0.89 (0.53–1.47)	–